(P-1187) Olorofim for the treatment of Central Nervous System (CNS) invasive fungal infections (IFI) in patients with limited or no treatment options: a sub-analysis of an open-label, single-arm, Phase 2b trial (Study 32; NCT03583164)

Tuesday, October 21, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Presenting Author(s)

Fariba Donovan, MD, PhD

Associate Professor
University of Arizona College of Medicine-Tucson
Tucson, Arizona, United States

GT

George R. Thompson III, MD

University of California, Davis Medical Center
Sacramento, California, United States
RJ

Royce Johnson, MD

Kern Medical Center
Bakersfield, California, United States
Martin Hoenigl, MD (he/him/his)

Accociate Professor for Translational Mycology
Medical University of Graz, Graz, Austria
Graz, Steiermark, Austria
Johan A. Maertens, MD PhD

Professor
UZ Leuven
Leuven, Vlaams-Brabant, Belgium
Andrej Spec, M.D., MSCI (he/him/his)

Associate Professor
Washington University School of Medicine in St. Louis
St. Louis, Missouri, United States
AD

Andrea Deschambeault, PharmD

F2G
Princeton, New Jersey, United States
VR

Valerie Ravenna, PharmD

F2G
Princeton, New Jersey, United States
Daniela Zinzi, MD (she/her/hers)

Vice President Clinical R&D
F2G
Vienna, Wien, Austria
OF

Omar Fernandez, MD

F2G
Macclesfield, England, United Kingdom
John H. Rex, MD

Chief Medical Officer
F2G
Princeton, New Jersey, United States